Clinical Trial Update: Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating nab-paclitaxel (Abraxane) in combination with gemcitabine and capecitabine (Xeloda) for pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemzar (gemcitabine)
• Xeloda (capecitabine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Pancreatic Neoplasms, Pancreatic Cancer | Phase 1 | Status: COMPLETED